These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Preclinical evaluation of [¹¹¹ In]-DOTA-trastuzumab for clinical trials. Alirezapour B; Jalilian AR; Rajabifar S; Mirzaii M; Moradkhani S; Pouladi M; Aslani G J Cancer Res Ther; 2014; 10(1):112-20. PubMed ID: 24762497 [TBL] [Abstract][Full Text] [Related]
24. In-vitro internalization and in-vivo tumor uptake of anti-EGFR monoclonal antibody LA22 in A549 lung cancer cells and animal model. Liu Z; Yu Z; He W; Ma S; Sun L; Wang F Cancer Biother Radiopharm; 2009 Feb; 24(1):15-24. PubMed ID: 19216631 [TBL] [Abstract][Full Text] [Related]
25. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Law CL; Gordon KA; Collier J; Klussman K; McEarchern JA; Cerveny CG; Mixan BJ; Lee WP; Lin Z; Valdez P; Wahl AF; Grewal IS Cancer Res; 2005 Sep; 65(18):8331-8. PubMed ID: 16166310 [TBL] [Abstract][Full Text] [Related]
26. Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination. Wilbur DS; Chyan MK; Hamlin DK; Vessella RL; Wedge TJ; Hawthorne MF Bioconjug Chem; 2007; 18(4):1226-40. PubMed ID: 17583925 [TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo targeting properties of iodine-123- or iodine-131-labeled monoclonal antibody 14C5 in a non-small cell lung cancer and colon carcinoma model. Burvenich I; Schoonooghe S; Cornelissen B; Blanckaert P; Coene E; Cuvelier C; Mertens N; Slegers G Clin Cancer Res; 2005 Oct; 11(20):7288-96. PubMed ID: 16243799 [TBL] [Abstract][Full Text] [Related]
28. Methods for radiolabelling of monoclonal antibodies. Tolmachev V; Orlova A; Andersson K Methods Mol Biol; 2014; 1060():309-30. PubMed ID: 24037848 [TBL] [Abstract][Full Text] [Related]
39. Development of [⁶⁴Cu]-DOTA-PR81 radioimmunoconjugate for MUC-1 positive PET imaging. Alirezapour B; Rasaee MJ; Jalilian AR; Rajabifar S; Mohammadnejad J; Paknejad M; Maadi E; Moradkhani S Nucl Med Biol; 2016 Jan; 43(1):73-80. PubMed ID: 26453525 [TBL] [Abstract][Full Text] [Related]
40. Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment. Luo TY; Tang IC; Wu YL; Hsu KL; Liu SW; Kung HC; Lai PS; Lin WJ Nucl Med Biol; 2009 Jan; 36(1):81-8. PubMed ID: 19181272 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]